PMID- 19543838
OWN - NLM
STAT- MEDLINE
DCOM- 20100301
LR  - 20091229
IS  - 1559-0291 (Electronic)
IS  - 0273-2289 (Linking)
VI  - 160
IP  - 1
DP  - 2010 Jan
TI  - Evaluation of antineoplastic activity of extracellular asparaginase produced by 
      isolated Bacillus circulans.
PG  - 72-80
LID - 10.1007/s12010-009-8679-8 [doi]
AB  - L-Asparaginase is an important component in the treatment of acute lymphoblastic 
      leukemia in children. Its antineoplastic activity toward malignant cells is due 
      to their characteristic nature in slow synthesis of L-asparagine (Asn), which 
      causes starvation for this amino acid, while normal cells are protected from Asn 
      starvation due to their ability to produce this amino acid. The relative 
      selectivity with regard to the metabolism of malignant cells forces to look for 
      novel asparaginase with little glutaminase-producing systems compared to existing 
      enzyme. In this investigation, the role of the extracellular asparaginase enzyme 
      produced by an isolated bacterial strain was studied. Biochemical 
      characterization denoted that this isolated bacterial strain belongs to the 
      Bacillus circulans species. The strain was tested for L-asparaginase production, 
      and it was observed that, under an optimized environment, this isolate produces a 
      maximum of 85 IU ml(-1) within 24-h incubation. This enzyme showed less (60%) 
      glutaminase activity compared to commercial Erwinia sp. L-asparaginase. The 
      partially purified enzyme showed an approximate molecular weight of 140 kDa. This 
      enzyme potency in terms of antineoplastic activity was analyzed against the 
      cancer cells, CCRF-CEM. Flow cytometry experiments indicated an increase of 
      sub-G1 cell population when the cells were treated with L-asparaginase.
FAU - Prakasham, R S
AU  - Prakasham RS
AD  - Bioengineering and Environmental Centre, Indian Institute of Chemical Technology, 
      Hyderabad, India. prakasam@iict.res.in
FAU - Hymavathi, M
AU  - Hymavathi M
FAU - Subba Rao, Ch
AU  - Subba Rao Ch
FAU - Arepalli, S K
AU  - Arepalli SK
FAU - Venkateswara Rao, J
AU  - Venkateswara Rao J
FAU - Kennady, P Kavin
AU  - Kennady PK
FAU - Nasaruddin, K
AU  - Nasaruddin K
FAU - Vijayakumar, J B
AU  - Vijayakumar JB
FAU - Sarma, P N
AU  - Sarma PN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090619
PL  - United States
TA  - Appl Biochem Biotechnol
JT  - Applied biochemistry and biotechnology
JID - 8208561
RN  - 0 (Antineoplastic Agents)
RN  - EC 3.5.1.1 (Asparaginase)
SB  - IM
MH  - Antineoplastic Agents/*metabolism/*pharmacology/therapeutic use
MH  - Asparaginase/*biosynthesis/*pharmacology/therapeutic use
MH  - Bacillus/cytology/*isolation & purification/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Extracellular Space/*enzymology
MH  - Humans
MH  - Leukemia/drug therapy
EDAT- 2009/06/23 09:00
MHDA- 2010/03/02 06:00
CRDT- 2009/06/23 09:00
PHST- 2008/09/24 00:00 [received]
PHST- 2009/05/18 00:00 [accepted]
PHST- 2009/06/23 09:00 [entrez]
PHST- 2009/06/23 09:00 [pubmed]
PHST- 2010/03/02 06:00 [medline]
AID - 10.1007/s12010-009-8679-8 [doi]
PST - ppublish
SO  - Appl Biochem Biotechnol. 2010 Jan;160(1):72-80. doi: 10.1007/s12010-009-8679-8. 
      Epub 2009 Jun 19.